Hansa Biopharma AB (publ)

LSE:0RC7 Stock Report

Market Cap: SEK 2.1b

Hansa Biopharma Valuation

Is 0RC7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RC7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0RC7's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0RC7's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RC7?

Key metric: As 0RC7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0RC7. This is calculated by dividing 0RC7's market cap by their current revenue.
What is 0RC7's PS Ratio?
PS Ratio11.1x
SalesSEK 189.39m
Market CapSEK 2.14b

Price to Sales Ratio vs Peers

How does 0RC7's PS Ratio compare to its peers?

The above table shows the PS ratio for 0RC7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.4x
AVCT Avacta Group
7.8x0.4%UK£182.9m
BVXP Bioventix
14.4xn/aUK£195.7m
TRX Tissue Regenix Group
1.6x15.1%UK£40.6m
AREC Arecor Therapeutics
5.9x35.2%UK£28.9m
0RC7 Hansa Biopharma
11.1x47.3%SEK 2.1b

Price-To-Sales vs Peers: 0RC7 is expensive based on its Price-To-Sales Ratio (11.1x) compared to the peer average (7.4x).

Price to Sales Ratio vs Industry

How does 0RC7's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.39b
OXB Oxford Biomedica
4.6x21.0%US$562.82m
TRX Tissue Regenix Group
1.6x15.1%US$51.10m
PBX ProBiotix Health
3.7xn/aUS$13.43m
0RC7 11.1xIndustry Avg. 8.0xNo. of Companies7PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0RC7 is expensive based on its Price-To-Sales Ratio (11.1x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0RC7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RC7 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.1x
Fair PS Ratio8.4x

Price-To-Sales vs Fair Ratio: 0RC7 is expensive based on its Price-To-Sales Ratio (11.1x) compared to the estimated Fair Price-To-Sales Ratio (8.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RC7 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 31.13
SEK 99.25
+218.8%
52.5%SEK 175.00SEK 46.00n/a4
Nov ’25SEK 36.54
SEK 100.00
+173.7%
51.5%SEK 175.00SEK 46.00n/a4
Oct ’25SEK 39.12
SEK 100.00
+155.6%
51.5%SEK 175.00SEK 46.00n/a4
Sep ’25SEK 55.40
SEK 100.00
+80.5%
51.5%SEK 175.00SEK 46.00n/a4
Aug ’25SEK 40.20
SEK 100.00
+148.8%
51.5%SEK 175.00SEK 46.00n/a4
Jul ’25SEK 46.18
SEK 105.00
+127.4%
44.7%SEK 175.00SEK 57.00n/a4
Jun ’25SEK 49.60
SEK 105.00
+111.7%
44.7%SEK 175.00SEK 57.00n/a4
May ’25SEK 28.64
SEK 105.00
+266.6%
44.7%SEK 175.00SEK 57.00n/a4
Apr ’25SEK 29.10
SEK 112.50
+286.6%
36.9%SEK 174.00SEK 57.00n/a4
Mar ’25SEK 31.71
SEK 112.50
+254.7%
36.9%SEK 174.00SEK 57.00n/a4
Feb ’25SEK 35.69
SEK 91.00
+155.0%
58.0%SEK 173.00SEK 16.00n/a5
Jan ’25SEK 26.79
SEK 108.33
+304.3%
57.1%SEK 195.00SEK 16.00n/a6
Dec ’24SEK 25.50
SEK 123.00
+382.4%
47.3%SEK 195.00SEK 16.00n/a6
Nov ’24SEK 23.10
SEK 123.00
+432.5%
47.3%SEK 195.00SEK 16.00SEK 36.546
Oct ’24SEK 34.40
SEK 167.50
+387.0%
22.4%SEK 224.00SEK 109.00SEK 39.126
Sep ’24SEK 44.28
SEK 167.50
+278.3%
22.4%SEK 224.00SEK 109.00SEK 55.406
Aug ’24SEK 54.07
SEK 167.50
+209.8%
22.4%SEK 224.00SEK 109.00SEK 40.206
Jul ’24SEK 42.51
SEK 168.50
+296.4%
23.8%SEK 224.00SEK 112.00SEK 46.186
Jun ’24SEK 46.18
SEK 168.50
+264.9%
23.8%SEK 224.00SEK 112.00SEK 49.606
May ’24SEK 50.21
SEK 171.29
+241.1%
19.8%SEK 224.00SEK 128.00SEK 28.647
Apr ’24SEK 50.88
SEK 176.83
+247.6%
22.8%SEK 241.00SEK 128.00SEK 29.106
Mar ’24SEK 53.57
SEK 176.83
+230.1%
22.8%SEK 241.00SEK 128.00SEK 31.716
Feb ’24SEK 61.93
SEK 177.60
+186.8%
24.9%SEK 245.00SEK 128.00SEK 35.695
Jan ’24SEK 49.08
SEK 176.20
+259.0%
26.0%SEK 245.00SEK 121.00SEK 26.795
Dec ’23SEK 54.76
SEK 176.20
+221.8%
26.0%SEK 245.00SEK 121.00SEK 25.505
Nov ’23SEK 53.75
SEK 186.50
+247.0%
25.6%SEK 245.00SEK 121.00SEK 23.106

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$749.75

7D

0.4%

1Y

-5.8%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

2.4%

1Y

12.5%